Polypill for Prevention of Cardiovascular Diseases

Polypill for Prevention of Cardiovascular Diseases – Authors' Reply Publisher Pubmed

Roshandel G^{1, 2} ; Kamangar F³ ; Marshall T⁴ ; Cheng KK⁴ ; Hemming K⁴ ; Malekzadeh R¹

Show Affiliations

1. Digestive Disease Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, 1411713135, Iran
2. Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
3. Department of Biology, School of Computer, Mathematical, and Natural Sciences, Morgan State University, Baltimore, MD, United States
4. Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom

Source: The Lancet Published:2020

Abstract

[No abstract available]

2. Polypill for the Prevention of Cardiovascular Disease (Polyiran): Study Design and Rationale for a Pragmatic Cluster Randomized Controlled Trial, European Journal of Preventive Cardiology (2015)

3. Cost-Effectiveness of Fixed-Dose Combination Pill (Polypill) in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Literature Review, PLoS ONE (2022)

4. Effectiveness of Polypill for Prevention of Cardiovascular Disease (Polypars): Protocol of a Randomized Controlled Trial, Archives of Iranian Medicine (2020)

Experts (# of related papers)

View all Related Experts

Reza Malekzadeh (3)

Hossein Poustchi (2)

Style	Citing Format
MLA	Roshandel G, et al.. "Polypill for Prevention of Cardiovascular Diseases – Authors' Reply." The Lancet, vol. 395, no. 10222, 2020, pp. 414-415.
APA	Roshandel G, Kamangar F, Marshall T, Cheng KK, Hemming K, Malekzadeh R (2020). Polypill for Prevention of Cardiovascular Diseases – Authors' Reply. The Lancet, 395(10222), 414-415.
Chicago	Roshandel G, Kamangar F, Marshall T, Cheng KK, Hemming K, Malekzadeh R. "Polypill for Prevention of Cardiovascular Diseases – Authors' Reply." The Lancet 395, no. 10222 (2020): 414-415.
Harvard	Roshandel G et al. (2020) 'Polypill for Prevention of Cardiovascular Diseases – Authors' Reply', The Lancet, 395(10222), pp. 414-415.
Vancouver	Roshandel G, Kamangar F, Marshall T, Cheng KK, Hemming K, Malekzadeh R. Polypill for Prevention of Cardiovascular Diseases – Authors' Reply. The Lancet. 2020;395(10222):414-415.
BibTex	@article{ author = {Roshandel G and Kamangar F and Marshall T and Cheng KK and Hemming K and Malekzadeh R}, title = {Polypill for Prevention of Cardiovascular Diseases – Authors' Reply}, journal = {The Lancet}, volume = {395}, number = {10222}, pages = {414-415}, year = {2020} }
RIS	TY - JOUR AU - Roshandel G AU - Kamangar F AU - Marshall T AU - Cheng KK AU - Hemming K AU - Malekzadeh R TI - Polypill for Prevention of Cardiovascular Diseases – Authors' Reply JO - The Lancet VL - 395 IS - 10222 SP - 414 EP - 415 PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract